Moleculin Biotech Inc
NASDAQ:MBRX
Moleculin Biotech Inc
NASDAQ:MBRX
Price:
2.32
USD
Market Closed
Market Cap:
$11.4m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Moleculin Biotech Inc
NASDAQ:MBRX
|
US |
|
Chugai Ro Co Ltd
TSE:1964
|
JP |
|
I
|
International Cement Group Ltd
SGX:KUO
|
SG |
|
Coda Octopus Group Inc
NASDAQ:CODA
|
US |
|
C&C Group PLC
LSE:CCR
|
IE |
|
Tclarke PLC
LSE:CTO
|
UK |
|
Tiziana Life Sciences Ltd
NASDAQ:TLSA
|
UK |
|
Proteomics International Laboratories Ltd
ASX:PIQ
|
AU |
|
L
|
Lloyds Banking Group PLC
NYSE:LYG
|
UK |
|
V
|
Vishay Precision Group Inc
NYSE:VPG
|
US |
|
J W Mays Inc
NASDAQ:MAYS
|
US |
|
M3 Inc
TSE:2413
|
JP |
|
Bonesupport Holding AB
STO:BONEX
|
SE |
|
I
|
Ianthus Capital Holdings Inc
CNSX:IAN
|
CA |
|
S
|
SMCG Co Ltd
KOSDAQ:460870
|
KR |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of MBRX.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
MBRX
Multiples-Based Value
Base Case
Not Available
Multiples Across Competitors
MBRX Competitors Multiples
Moleculin Biotech Inc Competitors
Moleculin Biotech Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Moleculin Biotech Inc
NASDAQ:MBRX
|
11.4m USD | 0 | -0.2 | -0.2 | -0.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
365.4B USD | 6 | 87.3 | 14.5 | 20.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
184.6B USD | 5 | 23.9 | 13.9 | 13.9 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173.9B USD | 5.9 | 20.5 | 12.8 | 15.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.3B USD | 9.2 | 27.9 | 20.9 | 21.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.7B USD | 5.6 | 17.9 | 13.4 | 15.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67B AUD | 3 | 33.2 | 11.2 | 14 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.6B EUR | 11.2 | 36 | 39.1 | 39.9 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
